Pfizer Inc.

NYSE:PFE

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

United States

Market Cap

USD 135.77 B

Share Price

USD 23.88

Avg Daily Volume

52,794,624

Change (1 day)

-0.50%

Change (1 year)

-12.88%

Change (YTD)

-9.99%

Pfizer Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 29, 2025: USD 13.99 B

Pfizer Inc. Operating Cash Flow is USD 13.99 B for the Trailing 12 Months (TTM) ending March 29, 2025, a 63.10% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Pfizer Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 8.58 B, a -64.17% change year over year.
Pfizer Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending April 02, 2023 was USD 23.94 B, a -30.78% change year over year.
Pfizer Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending April 03, 2022 was USD 34.58 B, a 118.77% change year over year.
Pfizer Inc. Operating Cash Flow for the Trailing 12 Months (TTM) ending April 04, 2021 was USD 15.81 B, a 12.73% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Operating Cash Flow	Capital Expenditure	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities

NYSE: PFE

Pfizer Inc.

CEO	Dr. Albert Bourla D.V.M., Ph.D.
IPO Date	June 1, 1972
Location	United States
Headquarters	235 East 42nd Street
Employees	81,000
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.